Minimal Residual Disease in Acute Lymphoblastic Leukemia: Current Practice and Future Directions.

ABSTRACT: Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer and advances in its clinical and laboratory biology have grown exponentially over the last few decades. Treatment outcome has improved steadily with over 90% of patients surviving 5 years from initial diagnosis. This success can be attributed in part to the development of a risk stratification approach to identify those subsets of patients with an outstanding outcome that might qualify for a reduction in therapy associated with fewer short and long term side effects. Likewise, recognition of patients with an inferior prognosis allows for augmentation of therapy, which has been shown to improve outcome. Among the clinical and biological variables known to impact prognosis, the kinetics of the reduction in tumor burden du

SUBMITTER: Contreras Yametti GP 

PROVIDER: S-EPMC8069391 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature